Published online January 2, 2008
PEDIATRICS Vol. 121 Supplement January 2008, pp. S164 (doi:10.1542/peds.2007-2022RRRRRRR)
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillet, Y.
Right arrow Articles by Ledesma, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gillet, Y.
Right arrow Articles by Ledesma, E.

VACCINATION


IMMUNOGENICITY AND SAFETY OF CONCOMITANT ADMINISTRATION OF MEASLES-MUMPS-RUBELLA VACCINE AND VARICELLA VACCINE BY THE INTRAMUSCULAR OR SUBCUTANEOUS ROUTE

Yves Gilleta, Pirmin Habermehlb, Anne Fiquetc, Stephane Thomasc, Cecile Eyminc, Isabelle Bertrandc and Emilio Ledesmac

a Urgences Pediatriques, Hôpital Edouard Herriot, Lyon, France
b Facharzt Fur Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim, Germany
c Sanofi Pasteur MSD, Marcy d'Etoide, France

ABSTRACT

INTRODUCTION: In Europe, recommended administration route for vaccines and physicians' preferences vary.

OBJECTIVE: The aim of this study was to compare the immunogenicity and safety profile (injection-site and systemic adverse events) of a measles-mumps-rubella vaccine (M-M-RvaxPRO) and a varicella vaccine (Varivax) when given by intramuscular or subcutaneous route.

METHODS: A total of 752 healthy children who were 12 to 18 months of age were randomly assigned to receive concomitantly at 2 separate injection sites 1 dose of both vaccines by the same route, either intramuscular or subcutaneous.

RESULTS: Six weeks after vaccination, response rates in patients who were initially seronegative were similar for all antigens (intramuscular noninferior to subcutaneous), and geometric mean titers were comparable irrespective of the administration route (Table 1). Similar numbers and types of systemic adverse events were observed in both groups, excepted for varicella/varicella-like rashes, which were less frequent in the intramuscular group. Injection-site reactions were also less frequent for both vaccines in the intramuscular group compared with the subcutaneous group (15.8% and 25.8% of patients for M-M-RvaxPRO and 20.9% and 34.3% for Varivax, respectively), but the safety pattern was comparable between groups.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Response Rates and Geometric Mean Titers of the Measles-Mumps-Rubella and Varicella Vaccines When Given by Different Routes

 
CONCLUSIONS: These results support both intramuscular and subcutaneous administration routes for M-M-RvaxPRO and Varivax.

Submitted by Yves Gillet